Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Amortization of Deferred Charges: 2009-2025

Historic Amortization of Deferred Charges for Northwest Biotherapeutics (NWBO) over the last 15 years, with Sep 2025 value amounting to $414,000.

  • Northwest Biotherapeutics' Amortization of Deferred Charges fell 24.86% to $414,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 7.41%. This contributed to the annual value of $2.5 million for FY2024, which is 4.38% up from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Amortization of Deferred Charges of $414,000 as of Q3 2025, which was down 21.14% from $525,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Amortization of Deferred Charges ranged from a high of $1.1 million in Q1 2021 and a low of $231,000 during Q2 2021.
  • In the last 3 years, Northwest Biotherapeutics' Amortization of Deferred Charges had a median value of $551,000 in 2024 and averaged $556,455.
  • The largest annual percentage gain for Northwest Biotherapeutics' Amortization of Deferred Charges in the last 5 years was 228.28% (2021), contrasted with its biggest fall of 68.36% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' Amortization of Deferred Charges (Quarterly) stood at $580,000 in 2021, then grew by 13.79% to $660,000 in 2022, then tumbled by 44.55% to $366,000 in 2023, then soared by 134.43% to $858,000 in 2024, then fell by 24.86% to $414,000 in 2025.
  • Its Amortization of Deferred Charges stands at $414,000 for Q3 2025, versus $525,000 for Q2 2025 and $334,000 for Q1 2025.